Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.54 |
| ▸ | CES1 | P23141 | 1/20 | 0.54 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | DBH | P09172 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 2/20 | 0.50 |
| ▸ | CA2 | P00918 | 2/20 | 0.50 |
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 5/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | TNNI3 | P19429 | 1/20 | 0.46 |
| ▸ | TNNT2 | P45379 | 1/20 | 0.46 |
| ▸ | TNNC1 | P63316 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2918747 | 0.94 | CES2 (0.48) | CES2CES1RECQLKDM4EDBH | |
| SCHEMBL9337960 | 0.88 | ESR1 (0.49) | CES2CES1RECQLKDM4EDBH | |
| SCHEMBL10121174 | 0.87 | KDM4E (0.62) | CES2CES1RECQLKDM4EDBH | |
| SCHEMBL5783383 | 0.84 | CES2 (0.52) | CES2CES1RECQLCA1CA2 | |
| SCHEMBL20703078 | 0.84 | CES2 (0.52) | CES2CES1RECQLCA1CA2 | |
| SCHEMBL23544612 | 0.84 | CES2 (0.52) | CES2CES1RECQLCA1CA2 | |
| SCHEMBL5011661 | 0.84 | CES2 (0.52) | CES2CES1RECQLCA1CA2 | |
| SCHEMBL634337 | 0.84 | CES2 (0.52) | CES2CES1RECQLCA1CA2 | |
| SCHEMBL7778212 | 0.82 | CES2 (0.50) | CES2CES1RECQLCA1CA2 | |
| SCHEMBL13825299 | 0.82 | CES2 (0.50) | CES2CES1RECQLCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | LYSOWAY THERAPEUTICS INC (US) | 2025-10-30 | — | — | US | disclosed |
| CN-115894447-B | METTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240109839-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | PRAZERTHERAPEUTICS INC. (KR) | 2024-04-04 | — | — | US | disclosed |
| EP-4289480-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | F. Hoffmann-La Roche AG (CH) | 2023-12-13 | — | — | EP | disclosed |
| CN-117136177-A | Novel compounds exhibiting anti-inflammatory activity as P38MAP kinase inhibitors | 普瑞泽治疗公司 | 2023-11-28 | — | — | CN | disclosed |
| US-11813278-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| EP-4273120-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | Prazertherapeutics Inc. (KR) | 2023-11-08 | — | — | EP | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. | 2023-09-14 | — | — | US | disclosed |
| US-11738038-B2 | Highly active compounds against COVID-19 | Atea Pharmaceuticals, Inc. (US) | 2023-08-29 | — | — | US | disclosed |
| EP-0391212-B1 | Process for preparing bifunctional Z-stilbene compounds, new bifunctional Z-stilbene compounds and their use for preparing polymers | BAYER AG (DE) | 1994-05-25 | — | — | EP | disclosed |
| US-5136013-A | Polyesters | BAYER AKTIENGESELLSCHAFT (DE) | 1992-08-04 | — | — | US | disclosed |
| EP-0273647-B1 | COUMARAN DERIVATIVES, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-03-11 | — | — | EP | disclosed |
| US-5068300-A | BIFUNCTIONAL STILBENE COMPOUNDS CONTAINING AT LEAST ONE Z-CONFIGURATED STILBENE GROUP, PROCESS FOR THEIR PREPARATION AND THEIR USE FOR THE PREPARATION OF POLYMERS | BAYER AKTIENGESELLSCHAFT (DE) | 1991-11-26 | — | — | US | disclosed |
| US-4857516-A | Coumaran derivatives and their pharmaceutical use | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-08-15 | — | — | US | disclosed |
| EP-0273647-A1 | Coumaran derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-07-06 | — | — | EP | disclosed |
| US-RE30634-E | INSECTICIDES | SHELL OIL COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| EP-0009865-A1 | Process for the stereoselective synthesis of the E isomer of aryl alkyl oximes | RHONE-POULENC INC. (US) | 1980-04-16 | — | — | EP | disclosed |
| US-4158015-A | Process for the stereoselective synthesis of the E isomer of aryl alkyl oximes | MOBIL OIL CORPORATION (US) | 1979-06-12 | — | — | US | disclosed |
| US-4079149-A | INSECTICIDES | SHELL OIL COMPANY (US) | 1978-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285573-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | NEDD4, CBL, UBQLN2 | CES2 3486/4885CES1 4185/4885RECQL 858/4885 |
| US-11813278-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CES2 1447/4885CES1 1964/4885RECQL 403/4885 |
| US-11738038-B2 | Highly active compounds against COVID-19 | PNP, ACE2, MTAP | CES2 1447/4885CES1 1964/4885RECQL 403/4885 |
| US-20250333406-A1 | SULFONYL CYCLIC DERIVATIVES, AND COMPOSITIONS AND METHODS THEREOF | STOML2, ATP2A3, ATP2A1 | CES2 1765/4885CES1 1397/4885RECQL 1282/4885 |
| US-20240109839-A1 | NOVEL COMPOUND EXHIBITING ANTI-INFLAMMATORY ACTIVITY AS P38 MAP KINASE INHIBITOR | MAPK1, MAPKAPK2, MAPKAPK5 | CES2 4496/4885CES1 2673/4885RECQL 4859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.